Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go

New England Journal of Medicine, 2017

Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, University of Miami, Stanford University, Dana-Farber Cancer Institute, Montefiore Medical Center, Vanderbilt University Medical Center, City Of Hope National Medical Center, Mayo Clinic in Arizona, University of California, Los Angeles, Loyola University Medical Center, University of Rochester, Sarah Cannon, Tennessee Oncology, Hackensack University Medical Center, Cleveland Clinic, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Iowa, Colorado Blood Cancer Institute, Tel Aviv Sourasky Medical Center, Tel Aviv University, Kite (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

5778

Citations

View on Google Scholar

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Abstract

Journal Details

Join JournalsHub

Welcome Back